How Big is the Heart Failure Market | Trends & Share 2031

What is the size of Heart Failure Market?

Heart failure market is predicted to rise in the upcoming years, driven by the global increase in cardiovascular diseases, aging population, and ongoing advancements in diagnostics, therapeutics, and disease management.

Key Growth Drivers of the Heart Failure Market

• Increasing global prevalence of heart failure and other chronic cardiovascular conditions
• Growing aging population and sedentary lifestyles contributing to higher risk factors
• Innovations in drug development, including SGLT2 inhibitors and ARNI therapy
• Government support and public-private initiatives for cardiac care infrastructure
• Improved diagnostic techniques and early detection boosting treatment demand

Heart Failure Market Trends

Heart failure market is evolving over the years with increasing adoption of combination therapies, AI-enabled risk stratification tools, and personalized treatment protocols. Another rising trend towards the integrated care models combining pharmacological and device-based treatments. Further, the patient-centric digital platforms are being leveraged to improve adherence and remote monitoring. Collectively, all these trends are reshaping the dynamics of the market.

Emerging Developments in the Heart Failure Market

Heart failure market is seeing emerging developments with gene-based therapy research, regenerative medicine approaches, and precision medicine for heart failure subtypes. On the other hand, startups have started exploring the digital therapeutics and remote cardiac rehabilitation platforms. Further, the telehealth-based heart failure clinics and predictive analytics tools are also entering the mainstream cardiac care frameworks.

List of Leading Companies in the Heart Failure Market

Below is a comprehensive list of the leading market players driving growth in this sector:

1. Novartis AG

Provides Entrestor, a breakthrough ARNI drug used in treating heart failure with reduced ejection fraction (HFrEF), widely adopted globally.

2. AstraZeneca

Offers SGLT2 inhibitors used in heart failure management across multiple clinical settings.

3. Bayer AG

Provides innovative treatment options like vericiguat for symptomatic chronic heart failure, addressing unmet therapeutic needs.

4. Merck & Co., Inc.

Actively involved in R&D of heart failure therapies, including combination drugs for cardiovascular care.

5. Amgen Inc.

Focuses on heart failure treatments including biologics and investigational agents to reduce hospitalization and preserve heart function.

6. Bristol-Myers Squibb

Engaged in clinical development of cardiovascular therapies targeting heart failure progression and inflammation.

7. Cytokinetics, Inc.

Develops cardiac muscle activators and myotropes to improve heart function in patients with heart failure.

8. Renova Therapeutics

Specializes in gene therapy products targeting congestive heart failure and other chronic cardiac diseases.

How Big is the Heart Failure Market : FAQs